13G Filing: RA Capital Management and Sunesis Pharmaceuticals Inc (SNSS)

Page 5 of 8 – SEC Filing

CUSIP No. 867328700 13G
Item 4. Ownership:

Provide the following information regarding
the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount Beneficially Owned:

See the response(s) to Item 9 on the attached cover page(s).

(b)

Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

(c) Number of shares as to which such person has:
  (i)

sole power to vote or to direct the vote:

See the response(s) to Item 5 on the attached cover page(s).

 
  (ii)

shared power to vote or to direct the vote

See the response(s) to Item 6 on the attached cover page(s).

 
  (iii)

sole power to dispose or to direct the disposition of

See the response(s) to Item 7 on the attached cover page(s).

 
  (iv)

shared power to dispose or to direct the disposition of

See the response(s) to Item 8 on the attached cover page(s).

 

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)